Lonza and industry leaders argue that automation and global manufacturing networks are essential to scale CAR T and CAR Treg therapies beyond current bottlenecks, emphasizing early process development and Quality by Design to avoid costly GMP failures. At the same time, Manifold Bio showcased a high-throughput in vivo discovery platform using massive biologics screens and AI to map tissue “portal” networks for targeted delivery — a potential route to improve therapeutic index and distribution for cell and biologic drugs.